Corticosteroids Sales

Corticosteroids Sales Market Outlook

The global corticosteroids market is estimated to reach approximately USD 12.5 billion by 2033, with a compound annual growth rate (CAGR) of around 4.5% during the forecast period of 2025-2033. The growth of this market can be attributed to the increasing prevalence of chronic inflammatory diseases, a rise in autoimmune disorders, and the growing awareness among healthcare professionals regarding the efficacy of corticosteroids in treating various conditions. Moreover, advancements in drug formulations and delivery methods are expected to further bolster market growth. The demand for effective treatments for respiratory diseases, coupled with the rising geriatric population susceptible to chronic illnesses, is predicted to significantly contribute to the expansion of the corticosteroids market. The ongoing research and development activities aimed at discovering new corticosteroid compounds are also anticipated to enhance market growth in the coming years.

Growth Factor of the Market

The corticosteroids market is driven by multiple factors that enhance its growth trajectory. One of the primary factors is the increasing incidence of inflammatory and autoimmune diseases, which require effective management strategies. The rising awareness about the benefits of corticosteroids among healthcare providers and patients plays a crucial role in this market's expansion, as these potent medications provide relief for a variety of conditions ranging from allergies to severe skin disorders. Additionally, advancements in pharmaceutical research have led to the development of novel corticosteroid formulations with improved safety profiles, fostering greater acceptance among prescribing physicians. The expansion of distribution channels, especially the rise of online pharmacies due to their convenience, has made corticosteroids more accessible to patients, further propelling market growth. Furthermore, the ongoing investments in healthcare infrastructure and the increasing focus on chronic disease management are expected to sustain the upward trend in corticosteroid sales.

Key Highlights of the Market

• Growing prevalence of chronic inflammatory diseases driving demand.
• Advancements in drug delivery systems improving efficacy and safety.
• Increasing awareness about the management of autoimmune disorders.
• Expansion in distribution channels, including online pharmacies.
• Rising geriatric population susceptible to chronic illnesses.

By Product Type

Creams:

Creams are a significant segment within the corticosteroids market, primarily utilized for localized treatment of dermatological conditions such as eczema, psoriasis, and dermatitis. The formulation of corticosteroid creams allows for easy application and absorption, making them a preferred choice for patients seeking targeted relief from skin inflammation and irritation. These topical agents offer a safer alternative to systemic corticosteroids, minimizing potential side effects while effectively reducing symptoms. The growing awareness of skin health and the increasing incidence of skin-related disorders play a pivotal role in driving the demand for corticosteroid creams. Furthermore, innovative formulations that combine corticosteroids with moisturizing agents are enhancing their therapeutic efficacy, further propelling their market share.

Ointments:

Corticosteroid ointments are another crucial segment known for their effectiveness in treating severe skin conditions. Unlike creams, ointments are thicker and provide a more occlusive barrier, which helps in locking in moisture and enhancing drug absorption. This formulation is particularly beneficial for treating chronic skin diseases where prolonged exposure to medication is required. The demand for ointments is expected to rise due to their effectiveness in providing relief from itching, redness, and inflammation associated with various dermatological conditions. Moreover, with dermatological problems on the rise, driven by factors such as environmental changes and increased sun exposure, the market for corticosteroid ointments is poised for significant growth in the coming years.

Injections:

Corticosteroid injections are widely used for the management of severe inflammatory conditions and pain relief. Common applications include treatment for conditions such as arthritis, bursitis, and tendonitis. This route of administration allows for high concentrations of medication to be delivered directly to the affected area, facilitating rapid relief of symptoms. The growing prevalence of musculoskeletal disorders, combined with the increasing acceptance of corticosteroid injections as part of comprehensive treatment regimens, has led to a marked rise in demand. Furthermore, advancements in injection techniques and guided imaging have improved the precision of these treatments, thereby enhancing patient outcomes, which positively influences market growth.

Tablets:

Corticosteroid tablets are a vital product type in the market, providing a systemic approach to treating a variety of conditions including inflammatory diseases, autoimmune disorders, and allergies. These oral medications offer the convenience of administration and are often prescribed for long-term management of chronic conditions. The increasing prevalence of respiratory diseases, such as asthma and chronic obstructive pulmonary disease (COPD), has significantly contributed to the demand for corticosteroid tablets. Moreover, ongoing research and development efforts to create extended-release formulations are expected to enhance the therapeutic index of these medications, thereby driving market growth.

Inhalers:

Inhalers represent a specialized segment of the corticosteroids market, particularly important for treating respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD). The use of inhalers enables targeted delivery of corticosteroids directly to the respiratory system, resulting in improved efficacy and minimized systemic side effects. The increasing prevalence of asthma and allergies, coupled with rising awareness about the importance of adherence to inhaler therapy, is driving the growth of this segment. Additionally, advancements in inhalation technology, including the development of smart inhalers equipped with monitoring capabilities, are enhancing patient engagement and medication compliance, further propelling the inhaler market.

By Application

Inflammatory Conditions:

The application of corticosteroids in managing inflammatory conditions is a major driver for market growth. Inflammatory diseases such as rheumatoid arthritis, eczema, and inflammatory bowel disease often require aggressive treatment to reduce inflammation and prevent complications. Corticosteroids are renowned for their potent anti-inflammatory properties, making them a cornerstone in the management of these conditions. The rising incidence of such disorders, coupled with the aging population at higher risk for inflammatory conditions, is propelling the demand for corticosteroids. Furthermore, continuous advancements in treatment protocols and the personalization of corticosteroid therapies are expected to enhance patient outcomes and boost market growth.

Autoimmune Disorders:

Corticosteroids play an essential role in the treatment of various autoimmune disorders, including lupus, multiple sclerosis, and psoriasis. These medications help modulate the immune response, reducing tissue damage and alleviating symptoms associated with these diseases. The increasing prevalence of autoimmune disorders, influenced by factors such as genetic predisposition and environmental triggers, is driving the demand for corticosteroids in this application area. With ongoing research uncovering new therapeutic uses for corticosteroids in autoimmune conditions, the market is expected to witness significant growth as more treatment options become available to patients.

Allergic Reactions:

Corticosteroids are frequently prescribed for the management of severe allergic reactions, including anaphylaxis and allergic rhinitis. Their effectiveness in controlling inflammation and immune responses makes them a preferred choice for acute allergic conditions. The growing prevalence of allergies, driven by environmental changes and lifestyle factors, is significantly contributing to the market demand for corticosteroids. Additionally, the increasing awareness about the health implications of untreated allergies and the importance of immediate intervention is expected to spur the use of corticosteroids for allergy management, thereby enhancing market growth.

Respiratory Diseases:

The use of corticosteroids in the management of respiratory diseases, especially asthma and COPD, is a key application area in the market. Corticosteroids help reduce inflammation in the airways, facilitating easier breathing and overall improved lung function. The escalating incidence of respiratory ailments, partly due to urbanization and increasing pollution levels, has led to a higher demand for corticosteroid treatments. Furthermore, advancements in inhalation technology, which improve drug delivery to the lungs, are making corticosteroids more effective, and thus, driving market expansion in this segment.

Dermatological Conditions:

Corticosteroids are widely utilized in treating dermatological conditions such as eczema, psoriasis, and dermatitis. These medications are crucial for managing inflammation, itching, and redness associated with skin disorders, making them a staple in dermatological practice. The increasing incidence of skin-related ailments, combined with the growing awareness about skin health, is expected to drive the demand for corticosteroids in this application area significantly. Additionally, the rise of telemedicine and online consultations has streamlined access to dermatological care, allowing more patients to receive timely treatment, thereby promoting the use of corticosteroids.

By Distribution Channel

Hospital Pharmacies:

Hospital pharmacies play a crucial role in the distribution of corticosteroids, particularly for patients requiring specialized treatments or those undergoing surgical procedures. These pharmacies are often responsible for managing complex medication regimens and ensuring that patients receive the necessary medications during their hospital stay. The rising number of hospital admissions due to chronic diseases and the increased emphasis on personalized medicine are driving the demand for corticosteroids through hospital pharmacies. Furthermore, collaborations between hospitals and pharmaceutical companies to provide comprehensive medication management services are expected to enhance the accessibility and utilization of corticosteroids in clinical settings.

Retail Pharmacies:

Retail pharmacies are a significant distribution channel for corticosteroids, providing convenient access for patients seeking over-the-counter or prescription medications. The increasing prevalence of dermatological and allergic conditions has led to a higher demand for topical corticosteroids available through retail outlets. Additionally, the growing trend of self-medication and increased health awareness among consumers are contributing to the rise in corticosteroid sales through retail pharmacies. Retail pharmacies are also focusing on improving patient engagement through educational initiatives and personalized services, which are expected to further enhance the sale of corticosteroids.

Online Pharmacies:

Online pharmacies have emerged as a vital distribution channel for corticosteroids, particularly during the COVID-19 pandemic, which accelerated the shift towards digital health solutions. The convenience of ordering medications from home and the availability of a wide range of corticosteroid products have driven the growth of this distribution channel. Online pharmacies often provide competitive pricing and fast shipping, making them an attractive option for consumers. The increasing acceptance of e-pharmacy models and the rise of telehealth services are expected to bolster the market for corticosteroids sold through online platforms while enhancing patient access to essential medications.

By Ingredient Type

Prednisone:

Prednisone is one of the most widely prescribed corticosteroids due to its potent anti-inflammatory effects and versatility in treating various conditions such as asthma, arthritis, and allergic reactions. It is available in multiple formulations, including tablets and injectable forms, making it accessible for different patient needs. The increasing prevalence of chronic inflammatory diseases is driving the demand for prednisone, as healthcare providers often favor its efficacy in managing acute exacerbations. Furthermore, ongoing research into novel applications of prednisone in treating other conditions is expected to further enhance its market share.

Hydrocortisone:

Hydrocortisone is a commonly used corticosteroid, particularly for topical applications in the treatment of dermatological conditions. Its effectiveness in reducing inflammation and providing symptomatic relief has made it a staple in both prescription and over-the-counter products. The growing incidence of skin disorders such as eczema and dermatitis is contributing to the increasing demand for hydrocortisone formulations. Additionally, the rise in pediatric patients requiring dermatological care is expected to further boost the sales of hydrocortisone-based products in the coming years, making it an important ingredient type in the corticosteroid market.

Dexamethasone:

Dexamethasone is a highly potent corticosteroid known for its anti-inflammatory and immunosuppressive properties. It is utilized in various therapeutic areas, including oncology, severe allergic reactions, and respiratory diseases. The COVID-19 pandemic highlighted the importance of dexamethasone in treating severe cases, significantly raising its profile in the pharmaceutical market. The growing awareness of the benefits of dexamethasone in critical care settings is expected to sustain its demand. Furthermore, research into its role in various diseases continues to uncover new applications, presenting opportunities for market growth.

Methylprednisolone:

Methylprednisolone is another key corticosteroid often used for its anti-inflammatory effects in conditions such as arthritis, allergies, and certain skin diseases. Its ability to provide rapid relief of symptoms makes it a preferred choice in acute care settings. The increasing prevalence of chronic inflammatory conditions is driving the demand for methylprednisolone, especially in injectable forms for outpatient treatment protocols. As healthcare providers become more familiar with its benefits in managing complex cases, the market for methylprednisolone is expected to grow steadily.

Betamethasone:

Betamethasone is widely used in both topical and systemic forms for managing various skin disorders, respiratory conditions, and inflammatory diseases. Its efficacy in controlling severe inflammation makes it a critical ingredient in many corticosteroid formulations. The rise in dermatological consultations and the increasing prevalence of skin diseases are contributing to the growing demand for betamethasone products. Additionally, advancements in formulation technology that enhance the bioavailability of betamethasone are expected to further drive its adoption in clinical practice.

By Region

The North American market for corticosteroids is expected to dominate the global market, accounting for approximately 40% of the total share. The high prevalence of chronic diseases, robust healthcare infrastructure, and significant investments in pharmaceutical research and development are critical factors contributing to this growth. Furthermore, the increasing awareness of corticosteroid treatments among healthcare providers and patients is expected to drive demand in this region. The market in North America is projected to grow at a CAGR of around 4.3% during the forecast period, fueled by innovations in drug delivery systems and the introduction of new corticosteroid products.

In Europe, the corticosteroids market is also witnessing substantial growth, driven by a rising geriatric population and an increasing incidence of chronic inflammatory and autoimmune disorders. The market in Europe is anticipated to account for approximately 30% of the total global share. The focus on personalized medicine and advancements in healthcare technologies are expected to enhance the availability and effectiveness of corticosteroid treatments. Moreover, regulatory support for the development of new formulations is likely to drive market growth, with a CAGR of around 4.1% forecasted for this region. The Asia Pacific region is gradually emerging as a key market, with an increasing share attributed to improving healthcare access and rising awareness of pharmaceutical therapies.

Opportunities

The corticosteroids market presents numerous opportunities for growth and innovation, particularly in the realm of new product development. As pharmaceutical companies invest in research and development, there is potential for the introduction of novel corticosteroid formulations that enhance efficacy while reducing side effects. For instance, the development of targeted delivery systems, such as biodegradable microspheres or nanocarriers, can optimize the therapeutic index of corticosteroids, improving patient adherence and outcomes. Additionally, the rising trend towards personalized medicine allows for tailored therapy options that cater to individual patient needs, thus broadening the scope for corticosteroid applications across different disease states.

Furthermore, the expansion of telemedicine and digital health platforms presents significant opportunities for the corticosteroids market. As more patients engage with healthcare providers remotely, there is a growing need for effective management of chronic conditions that corticosteroids address. This shift not only improves patient access to necessary treatments but also facilitates early intervention strategies, reducing the severity of disease states. The integration of digital health monitoring tools may also empower patients to manage their medications effectively, leading to improved treatment adherence and overall satisfaction. As the market adapts to these evolving trends, corticosteroids are likely to find new avenues for growth.

Threats

Despite the promising outlook for the corticosteroids market, several threats could hinder its growth trajectory. One significant concern is the potential for adverse effects associated with long-term corticosteroid use, including increased susceptibility to infections, weight gain, and osteoporosis. These side effects can lead to patient hesitancy in using corticosteroid therapies, thereby impacting sales. Furthermore, the emergence of alternative therapies, such as biologics for inflammatory and autoimmune conditions, poses a competitive threat to the corticosteroids market. As these newer treatment options gain traction, they may divert patients away from traditional corticosteroid therapies, prompting pharmaceutical companies to reassess their product strategies.

Additionally, regulatory challenges in the pharmaceutical industry could also impact the corticosteroids market. The complexity of the drug approval process, coupled with stringent regulations governing drug development and marketing, may slow down the introduction of innovative corticosteroid products. This could pose a significant barrier for companies seeking to capitalize on emerging market opportunities. Furthermore, ongoing economic fluctuations and potential changes in healthcare policies may also affect healthcare expenditure patterns, potentially limiting access to corticosteroid treatments for certain patient populations.

Competitor Outlook

• Pfizer Inc.
• GlaxoSmithKline plc
• Sanofi S.A.
• Bristol-Myers Squibb Company
• AbbVie Inc.
• Novartis AG
• Merck & Co., Inc.
• Teva Pharmaceutical Industries Ltd.
• Hikma Pharmaceuticals PLC
• Amgen Inc.
• Roche Holding AG
• Johnson & Johnson
• Allergan plc
• Sun Pharmaceutical Industries Ltd.
• AstraZeneca plc

The competitive landscape of the corticosteroids market is characterized by a mix of established pharmaceutical companies and emerging players. Major companies are continuously investing in research and development to innovate and expand their product portfolios. This includes the development of new formulations and delivery systems that enhance the therapeutic effects of corticosteroids while minimizing side effects. The market is also witnessing strategic collaborations and partnerships aimed at leveraging complementary strengths, enhancing product offerings, and accelerating market penetration. Companies are focusing on enhancing their distribution networks, particularly through online platforms, to improve accessibility of corticosteroid therapies and cater to the evolving needs of patients.

Among the leading players, Pfizer Inc. is known for its strong portfolio of corticosteroids, including innovative formulations that address various disease states. GlaxoSmithKline plc has been focusing on expanding its respiratory portfolio with corticosteroids, particularly inhalers, to cater to the growing demand in this area. Sanofi S.A. has made significant strides in the corticosteroids market with its wide range of formulations for both topical and systemic use. Bristol-Myers Squibb Company has been actively involved in research to uncover new therapeutic applications for existing corticosteroids, thereby strengthening its market position.

AbbVie Inc. has positioned itself as a strong competitor in the corticosteroids market, particularly in the area of autoimmune diseases, with products that effectively manage symptoms and improve patient quality of life. Novartis AG, known for its commitment to innovation, has been investing in the development of novel corticosteroid therapies that leverage advanced delivery systems. Merck & Co., Inc. continues to enhance its market presence through strategic acquisitions and partnerships, aiming to diversify its corticosteroid offerings and capitalize on emerging market opportunities. Overall, the competitive landscape of the corticosteroids market is dynamic, with companies striving to differentiate their products and solutions to gain a competitive edge.

• 1 Appendix

  • 1.1 List of Tables
  • 1.2 List of Figures

• 2 Introduction

  • 2.1 Market Definition
  • 2.2 Scope of the Report
  • 2.3 Study Assumptions
  • 2.4 Base Currency & Forecast Periods

• 3 Market Dynamics

  • 3.1 Market Growth Factors
  • 3.2 Economic & Global Events
  • 3.3 Innovation Trends
  • 3.4 Supply Chain Analysis

• 4 Consumer Behavior

  • 4.1 Market Trends
  • 4.2 Pricing Analysis
  • 4.3 Buyer Insights

• 5 Key Player Profiles

  • 5.1 Amgen Inc.
    • 5.1.1 Business Overview
    • 5.1.2 Products & Services
    • 5.1.3 Financials
    • 5.1.4 Recent Developments
    • 5.1.5 SWOT Analysis
  • 5.2 AbbVie Inc.
    • 5.2.1 Business Overview
    • 5.2.2 Products & Services
    • 5.2.3 Financials
    • 5.2.4 Recent Developments
    • 5.2.5 SWOT Analysis
  • 5.3 Novartis AG
    • 5.3.1 Business Overview
    • 5.3.2 Products & Services
    • 5.3.3 Financials
    • 5.3.4 Recent Developments
    • 5.3.5 SWOT Analysis
  • 5.4 Pfizer Inc.
    • 5.4.1 Business Overview
    • 5.4.2 Products & Services
    • 5.4.3 Financials
    • 5.4.4 Recent Developments
    • 5.4.5 SWOT Analysis
  • 5.5 Sanofi S.A.
    • 5.5.1 Business Overview
    • 5.5.2 Products & Services
    • 5.5.3 Financials
    • 5.5.4 Recent Developments
    • 5.5.5 SWOT Analysis
  • 5.6 Allergan plc
    • 5.6.1 Business Overview
    • 5.6.2 Products & Services
    • 5.6.3 Financials
    • 5.6.4 Recent Developments
    • 5.6.5 SWOT Analysis
  • 5.7 AstraZeneca plc
    • 5.7.1 Business Overview
    • 5.7.2 Products & Services
    • 5.7.3 Financials
    • 5.7.4 Recent Developments
    • 5.7.5 SWOT Analysis
  • 5.8 Roche Holding AG
    • 5.8.1 Business Overview
    • 5.8.2 Products & Services
    • 5.8.3 Financials
    • 5.8.4 Recent Developments
    • 5.8.5 SWOT Analysis
  • 5.9 Johnson & Johnson
    • 5.9.1 Business Overview
    • 5.9.2 Products & Services
    • 5.9.3 Financials
    • 5.9.4 Recent Developments
    • 5.9.5 SWOT Analysis
  • 5.10 Merck & Co., Inc.
    • 5.10.1 Business Overview
    • 5.10.2 Products & Services
    • 5.10.3 Financials
    • 5.10.4 Recent Developments
    • 5.10.5 SWOT Analysis
  • 5.11 GlaxoSmithKline plc
    • 5.11.1 Business Overview
    • 5.11.2 Products & Services
    • 5.11.3 Financials
    • 5.11.4 Recent Developments
    • 5.11.5 SWOT Analysis
  • 5.12 Hikma Pharmaceuticals PLC
    • 5.12.1 Business Overview
    • 5.12.2 Products & Services
    • 5.12.3 Financials
    • 5.12.4 Recent Developments
    • 5.12.5 SWOT Analysis
  • 5.13 Bristol-Myers Squibb Company
    • 5.13.1 Business Overview
    • 5.13.2 Products & Services
    • 5.13.3 Financials
    • 5.13.4 Recent Developments
    • 5.13.5 SWOT Analysis
  • 5.14 Sun Pharmaceutical Industries Ltd.
    • 5.14.1 Business Overview
    • 5.14.2 Products & Services
    • 5.14.3 Financials
    • 5.14.4 Recent Developments
    • 5.14.5 SWOT Analysis
  • 5.15 Teva Pharmaceutical Industries Ltd.
    • 5.15.1 Business Overview
    • 5.15.2 Products & Services
    • 5.15.3 Financials
    • 5.15.4 Recent Developments
    • 5.15.5 SWOT Analysis

• 6 Market Segmentation

  • 6.1 Corticosteroids Sales Market, By Application
    • 6.1.1 Inflammatory Conditions
    • 6.1.2 Autoimmune Disorders
    • 6.1.3 Allergic Reactions
    • 6.1.4 Respiratory Diseases
    • 6.1.5 Dermatological Conditions
  • 6.2 Corticosteroids Sales Market, By Product Type
    • 6.2.1 Creams
    • 6.2.2 Ointments
    • 6.2.3 Injections
    • 6.2.4 Tablets
    • 6.2.5 Inhalers
  • 6.3 Corticosteroids Sales Market, By Ingredient Type
    • 6.3.1 Prednisone
    • 6.3.2 Hydrocortisone
    • 6.3.3 Dexamethasone
    • 6.3.4 Methylprednisolone
    • 6.3.5 Betamethasone
  • 6.4 Corticosteroids Sales Market, By Distribution Channel
    • 6.4.1 Hospital Pharmacies
    • 6.4.2 Retail Pharmacies
    • 6.4.3 Online Pharmacies

• 7 Competitive Analysis

  • 7.1 Key Player Comparison
  • 7.2 Market Share Analysis
  • 7.3 Investment Trends
  • 7.4 SWOT Analysis

• 8 Research Methodology

  • 8.1 Analysis Design
  • 8.2 Research Phases
  • 8.3 Study Timeline

• 9 Future Market Outlook

  • 9.1 Growth Forecast
  • 9.2 Market Evolution

• 10 Geographical Overview

  • 10.1 Europe - Market Analysis
    • 10.1.1 By Country
      • 10.1.1.1 UK
      • 10.1.1.2 France
      • 10.1.1.3 Germany
      • 10.1.1.4 Spain
      • 10.1.1.5 Italy
  • 10.2 Asia Pacific - Market Analysis
    • 10.2.1 By Country
      • 10.2.1.1 India
      • 10.2.1.2 China
      • 10.2.1.3 Japan
      • 10.2.1.4 South Korea
  • 10.3 Latin America - Market Analysis
    • 10.3.1 By Country
      • 10.3.1.1 Brazil
      • 10.3.1.2 Argentina
      • 10.3.1.3 Mexico
  • 10.4 North America - Market Analysis
    • 10.4.1 By Country
      • 10.4.1.1 USA
      • 10.4.1.2 Canada
  • 10.5 Corticosteroids Sales Market by Region
  • 10.6 Middle East & Africa - Market Analysis
    • 10.6.1 By Country
      • 10.6.1.1 Middle East
      • 10.6.1.2 Africa

• 11 Global Economic Factors

  • 11.1 Inflation Impact
  • 11.2 Trade Policies

• 12 Technology & Innovation

  • 12.1 Emerging Technologies
  • 12.2 AI & Digital Trends
  • 12.3 Patent Research

• 13 Investment & Market Growth

  • 13.1 Funding Trends
  • 13.2 Future Market Projections

• 14 Market Overview & Key Insights

  • 14.1 Executive Summary
  • 14.2 Key Trends
  • 14.3 Market Challenges
  • 14.4 Regulatory Landscape

Segments Analyzed in the Report

The global Corticosteroids Sales market is categorized based on

By Product Type

• Creams
• Ointments
• Injections
• Tablets
• Inhalers

By Application

• Inflammatory Conditions
• Autoimmune Disorders
• Allergic Reactions
• Respiratory Diseases
• Dermatological Conditions

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

By Ingredient Type

• Prednisone
• Hydrocortisone
• Dexamethasone
• Methylprednisolone
• Betamethasone

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Key Players

• Pfizer Inc.
• GlaxoSmithKline plc
• Sanofi S.A.
• Bristol-Myers Squibb Company
• AbbVie Inc.
• Novartis AG
• Merck & Co., Inc.
• Teva Pharmaceutical Industries Ltd.
• Hikma Pharmaceuticals PLC
• Amgen Inc.
• Roche Holding AG
• Johnson & Johnson
• Allergan plc
• Sun Pharmaceutical Industries Ltd.
• AstraZeneca plc